Enoximone

Research use only, not for human use.

Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.

Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.Perioperative Enoximone administration improved renal function in patients undergoing on-pump cardiac surgery.(In Vitro):In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils.(In Vivo):Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation.The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.

In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils.

Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation.The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.

——

Angiogenesis

PDE

PDE3

——

——

77671-31-9

248.3

C12H12N2O2S

>98% (HPLC)

In Vitro:?DMSO : 8.33 mg/mL (33.55 mM)

CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C

——

(-20℃)

With Ice Pack

≥ 2 years